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Introduction
Plasma concentrations of N-terminal pro B-type natriuretic peptide (NT-proBNP) are strongly associated with prognosis in patients with chronic heart failure (CHF). [1] [2] [3] [4] [5] Prognostic models of CHF are generally based on a single assessment but in clinical practice risk varies over time as disease progresses, complications and co-morbidities develop and treatment that is intended to reduce risk is implemented. In clinical practice, health professionals evaluate risk serially. In clinical trials, the effect of treatment on NT-proBNP has often predicted outcome, 6 although this may not be true for some interventions such as beta-blockers. Recently the use of repeated measurements of NT-proBNP for predicting outcome have been studied for some chronic and acute setting (Supplementary Table S1 ). However, the prognostic value of serial measurements of natriuretic peptides for the assessment of changes in long-term risk in clinical practice has rarely been investigated and the value of doing so is uncertain. Some risk markers will be relatively fixed (eg:-age, sex and aetiology of disease) but other will be dynamic and fluctuate (for example, renal function). If serial measurements of NT-proBNP are more strongly related to prognosis than a single baseline value, it may be a dynamic marker that can be used to track risk.
The purpose of the present study was to investigate the relationship between all-cause mortality and repeated measurements of NT-proBNP compared with a single baseline or most recent value of NT-proBNP.
Methods

Study Population
Patients referred to a community heart failure clinic (Kingston-upon-Hull, UK) for the assessment of heart failure symptoms were invited to participate. A history and examination were performed, and patients underwent electrocardiography, echocardiography and had routine haematology and biochemical investigations. If heart failure was confirmed, patients were offered serial follow-up in the heart failure clinic. NT-proBNP was measured at baseline, and then at approximately 4 months, 12 months and yearly thereafter. Only patients who had one or more follow-up measurements of NT-proBNP were included in this analysis.
Samples for the measurement of NT-proBNP were collected in ethylene-diamine-tetra-acetic tubes, spun at 3000 r.p.m for 15 minutes in a cooled (4°C) centrifuge and the plasma was stored at -80°C until batch analysed using the Elecsys proBNP assay (Roche Diagnostics, Basel, Switzerland).
Prospectively collected clinical data and blood samples from a single heart failure clinic were used in this study. The primary outcome of interest was all-cause mortality. Data for deaths were collected from the hospital's electronic systems, supplemented by information from patients, discharge letters and their family doctors.
Prior to inclusion, all patients provided written informed consent for their data to be used and the study was carried out in accordance with the Helsinki Declaration II and the European Standards for Good Clinical Practice. Ethical approval was granted by the Hull and East
Yorkshire Local Research Ethics Committee. For the longitudinal sub-model the random effects of both intercept and slope were included to allow variations in each individually. Baseline age, sex, estimated glomerular filtration rate (eGRF)
Statistical methods
Continuous
were used as the fixed effects, and an interaction between time and heart rhythm was included. For the Cox-regression sub-model, pre-specified baseline variables included age, sex, and eGFR were used. Individual patient prediction was conducted according to the trajectory of NT-proBNP.
Statistical analysis was carried out using R version 3.0.1 and Stata software package. The twotailed level of statistical significance was set at p<0.05.
Results
Of 1,998 patients with at least two measurements of NT-proBNP, 70% were men. At baseline, their median age was 73 (IQR: 64-79) years, 31% were in NYHA class III/IV and 77% had
. Overall three-year mortality for patients with at least two measurements was 12.7%.
Patients who died at 3 years were older and more likely to be men, have ischaemic heart disease (IHD) and more severe symptoms, more likely to have atrial fibrillation, COPD and had a lower eGFR, systolic BP and haemoglobin, and higher heart rate and NT-proBNP than those who survived. Patients who survived were more likely to be prescribed beta-blockers and ACEi/ARBs (Table 1) .
There were strong positive linear correlations between baseline log(NT-proBNP) and each of repeated measurements of log(NT-proBNP) at 4 months, 12 months and 24 months regardless of heart rhythm (supplementary Table S2 ). Patients in atrial fibrillation had a consistently higher and patients in sinus rhythm consistently had lower median plasma NTproBNP at all time-points. Correlations were stronger for closer time-points ( Figure 1, supplementary Table S2 ).
Baseline NT-proBNP, time-dependent covariate NT-proBNP and most recent NT-proBNP were all significant predictors of all-cause mortality at 3 years (Table 2 ) (p<0.0001 for all).
Serial measurements and the most recent NT-proBNP were better predictors of prognosis than were baseline values. Similar results were obtained when the models were adjusted for age and sex.
1,998 patients with baseline and follow-up values for NT-proBNP (N=10,362) were included in the joint-modelling analysis, of whom 770 (39%) died. The median (IQR) follow-up time was 4.8 (2.5-8.6) years. The minimum follow-up time was 0.3 years and the maximum was 13.7 years.
There was a strong association between serial NT-proBNP values as a time-dependent covariate and all-cause mortality (Supplementary Table S3 
Discussion
To the best of our knowledge, this is the first paper to apply joint-modelling to study the dynamic association between serial measurements of NT-proBNP and survival. It suggests that NT-proBNP is a useful measurement for monitoring changes in prognosis, and presumably reflects the combined effects of disease progression, response to therapy and, for some, recovery of cardiac function. 9 Clearly, there must be a relationship between changes in and values of NT-proBNP but the most recent value of NT-proBNP conveys the most important prognostic information. 10 Our results cannot be taken as evidence that pursuing a particular target for NT-proBNP is the correct approach, as confirmed by the recent GUIDE-IT trial. 11 Basing clinical decisions on a single measurement is simple and has several other advantages. Previous measurements may not be available. Measuring change is also complex. Hopefully, one day, the aim will be to return values of NT-proBNP observed in patients with heart failure back into the normal range for the healthy population, although, despite implementation of guideline-recommended therapies, this rarely occurred in this cohort of patients. Further advances in the treatment of heart failure may increase the proportion of patients that achieve a normal value for NT-proBNP and if associated with control of symptoms and a good prognosis, this might be termed 'remission' of heart failure. 12 Numerous studies have shown the prognostic value of natriuretic peptides for patients with chronic heart failure and various other medical conditions. 12, 10, 13-20 However, they have not proved consistently valuable for assessing prognosis in acute heart failure (Supplementary Table S1_A) . [21] [22] [23] [24] [25] [26] [27] Curiously, this may reflect their ability to track changing prognostic risk rather than their failure. A patient with decompensated heart failure, left untreated, is near to death. Treatment will usually reduce NT-proBNP and improve prognosis. If natriuretic peptides were good prognostic markers in the acute setting, this would imply that they did not track with changing prognosis. In this setting, changes in natriuretic peptides might possibly provide additional information to achieved values, 24, 28 but when patients enter a more stable chronic phase of their illness our results are likely to apply.
Few studies 10, 14, 17 have examined the relationship of changes in natriuretic peptides and outcome in out-patients with chronic heart failure [Supplementary Table S1_B ]. In a small sample of patients with much fewer measurements of NT-proBNP and over a much shorter time-frame, we found similar results. 16 In a study of 2975 elderly adults without heart failure in whom NT-proBNP had been measured twice, 2-3 years apart, the second measurement further improved prediction of incident heart failure and cardiovascular death. 29 However, the possibility that baseline values added nothing to the follow-up value was not explored.
The prognostic value of natriuretic peptides appears similar for most if not all phenotypes of chronic heart failure. 13, 14, 16 However, for each of these phenotypes, plasma concentrations of NT-proBNP were relatively stable for most patients despite attempts to control symptoms and deliver guideline-recommended therapy.
Previous analyses have often failed to take into account the possibility that serial measurements of NT-proBNP are highly correlated. [13] [14] [15] Joint modelling of longitudinal and survival data is useful since it reduces the bias in estimating the association between repeated measurements and time to event 8 and provides an updated individual survival probability when a new measurement of NT-proBNP becomes available.
Limitations: An important limitation is that joint modelling, currently, allows only one variable (NT-proBNP in this case) to be used serially in the model. In addition, we have not reported rates of ICD/CRT implantation at baseline, partly because implant rates were low, and partly because many patients had a device implanted during follow up. Furthermore, the c-statistics we report are invariably much less than 1 reflects the impact of other variables, such as renal function and co-morbidities, on outcome. However, the aim of the study was to explore whether the history of how the NT-proBNP reached its present value matters. We have therefore not used further complex modelling to include all possible variables in all possible models to maximise the value for c-statistics.
Supplementary table S2 shows how we did not have data at every time point in each subject. However, one of the advantages of using joint modelling is that it can cope with missing values and does not require equal time intervals of longitudinal data. Further studies are needed to validate the findings.
Conclusions
In conclusion, serial measurement of NT-proBNP may be useful to monitor changes in prognostic risk but it is the last measured value that carries the most information. 
